Jiangsu Hengrui Pharmaceuticals (01276) plans to adopt the H-share stock plan for 2026.
Hengrui Medicine (01276) announced that on August 19, 2026, the board of directors has decided to propose the adoption of the 2026 H Share Plan (2026H). The 2026 H Share Plan will take effect upon approval at the upcoming first extraordinary general meeting of shareholders () in 2026.
Jiangsu Hengrui Pharmaceuticals (01276) announced that on August 19, 2026, the Board of Directors has resolved to propose the adoption of the 2026 H Share Stock Plan (2026 H Share Stock Plan). The 2026 H Share Stock Plan will take effect after being approved at the upcoming first extraordinary general meeting of shareholders (Shareholders' Meeting) of the Company in 2026.
Related Articles
US Stock Market Move | KINGSOFT CLOUD (KC.US) soared over 11%, with Q2 revenue growing by 30.8% year-on-year, setting a new historical high for a single quarter.
CTR HOLDINGS (01416) has won the bid for land located in Geylang, Singapore.
KINTOR PHARMA-B (09939) released its interim results, reporting a net loss of 75.782 million yuan, a year-on-year decrease of 8.99%.
US Stock Market Move | KINGSOFT CLOUD (KC.US) soared over 11%, with Q2 revenue growing by 30.8% year-on-year, setting a new historical high for a single quarter.
CTR HOLDINGS (01416) has won the bid for land located in Geylang, Singapore.
KINTOR PHARMA-B (09939) released its interim results, reporting a net loss of 75.782 million yuan, a year-on-year decrease of 8.99%.
RECOMMEND
